3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Not yet recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Rectal Neoplasms
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Stomach Neoplasms
3
Oligodendroglioma
3
Mouth Neoplasms
3
Lung Neoplasms
3
Glioma
3
Esophageal Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Meningioma
2
Melanoma
2
Gliosarcoma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma Of Esophagus
2
Xerostomia
1
Interventions
Gemcitabine
8
Capecitabine
6
pembrolizumab
5
Carboplatin
5
Pemetrexed
3
Paclitaxel
3
Oxaliplatin
3
Irinotecan
3
regorafenib
2
osimertinib
2
Taxes
2
Sunitinib
2
Radiotherapy
2
Fluorouracil
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
trifluridine tipiracil drug combination
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
sintilimab
1
seribantumab
1
selinexor
1
ruxolitinib
1
rubitecan
1
pralsetinib
1
palbociclib
1
olaparib
1
niraparib
1
linifanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Adenocarcinoma
×
Surgical Procedures, Operative
×
Clear all
NCT01419002
2015-07-29
Net-Pac
CHIR-Net
Phase 3
Terminated
5 enrolled